Company intelligence / Profile preview

Spirox, Inc.

Menlo Park (former), California, United Statesspirox.com.tw ↗

Ownership: Private
Employees: ~34
Development stage: Preclinical

Overview

Clinical studies showed that patients who received the LATERA implant experienced a 53.1% reduction in nasal obstruction symptoms at one year, with results in the range of more invasive techniques and without cosmetic downsides[6]. The device provides significant quality-of-life improvement through one year for nasal obstruction patients with lateral cartilage weakness.

Therapeutic areas: Pulmonology
Modalities: Medical implants
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Spirox, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spirox, Inc..

Explore the full profile